 The study tested the ability of the emulsion-based adjuvant de luvac forte registered trademark symbol to enhance the immunogenicity of a naked DNA vaccine encoding influenza proteins in mice. The results showed that the adjuvant significantly enhanced the potency and balance of the humeral response while having no significant impact on cellular immunity. This study represents an advancement toward effective DNA vaccines. This article was offered by Ingrid Coulson, Marie Borgren, Jens Nielsen, and others.